Open

Phase 3 study of trasuzumabe Deruxtecan versus trastuzumab emtansine in high-risk HER2+ breast cancer patients following neoadjuvant therapy

To evaluate initial basic feasible outcome with T-DXd treatment as compared to T-DM1 treatment.

Age & Gender

18 years ~ 99 years
Female

Visit Availability

Standard business hours (M-F, 8-5)

Location

United States (Nationwide)

What will be asked of you

At each visit you will meet with a member of the study team and complete a physical exam, weight, answer a questionnaire, and complete vital signs. The study may also involve blood draws, ECGs, ECHOS, and CTs of the chest.

In-person visits:
10-20

Phone or online visits:
10

Total length of participation:
five years

Looking for Specific Volunteers

Able to participate:

HER2 positive breast cancer
18 years or older

Not eligible if:

History of prior breast cancer
overall response of progressivedisease
Prior treatment with current drug regime for study

Contact the Team

Visit Location

Contact & Visit Location

Primary Contact

Primary Visit Location

Danny Talbot Cancer Center
UNC Cancer Care at Nash
2460 Curtis Ellis Dr, Rocky Mount, NC 27804, USA

Additional Study Information

Principal Investigator

Elie Choufani
UNC Hospitals - Nash

Study Type

Clinical or Medical
Interventional

Study Topics

Cancer (Breast)
Women's Health

IRB Number

20-3336

ClinicalTrials.gov

NCT04622319

Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Helpful Links

Questions?

This email address is being protected from spambots. You need JavaScript enabled to view it.